Spironolactone in Adult Congenital Heart Disease
Completed · Phase 2 · Has a placebo group
Conditions studied: Congenital Heart Disease, Heart Failure, Endomyocardial Fibrosis
In brief
The purpose of this study is to see if the study drug called spironolactone reduces fibrous (stiffening) in heart muscle tissue and improves heart function. Subjects from the study titled "Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis" who have evidence of heart dysfunction and/or evidence of fibrosis (stiffening) in the heart muscle will be asked to take part in this study.
Key facts
- Study ID
- NCT01069510
- Run by
- Oregon Health and Science University
- People needed
- 40
- Starts
- 2010-02-01
- Expected to finish
- 2017-03-01
- Last updated by the study team
- 2019-08-21
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Fibrosis index ≥29%, or
- Evidence of cardiovascular dysfunction including any of the following:
- Systemic ejection fraction <55%,
- NYHA 2-3
- 6-minute walk distance <500 m.
- Completion of Visit 1 of the study Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis" (eIRB # 3665) including meeting all inclusion for that study (Aged 18-80, Known congenital heart disease).
- Tetralogy of Fallot, cyanotic congenital heart disease, or a systemic right ventricle.
You may not qualify if…
- Patient currently taking spironolactone or previously taking spironolactone within the last 6 months.
- Serum potassium ≥5.0 mmol/L at the initial visit, if not taking potassium supplements. Patients will be eligible if a repeat potassium is <5.0 mmol/L after potassium supplements have been discontinued.
- Moderate/severe systemic atrioventricular valve regurgitation,
- Likely to undergo cardiac surgery, pacemaker implantation, or possible transplantation within one year (all self-reported),
- Unwilling to commit to return visits including mandatory blood draws for potassium,
- Renal insufficiency (estimated creatinine clearance < 30 ml/min/1.73m2),
- Positive urine pregnancy test.
- Any contraindication to MRI.
Where it is running
- Oregon Health & Science University — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.